Literature DB >> 11287053

Plasma homovanillic acid in untreated schizophrenia--relationship with symptomatology and sex.

Z J Zhang1, M Peet, C N Ramchand, S Shah, G P Reynolds.   

Abstract

Plasma homovanillic acid (pHVA) concentrations are considered to reflect, in part, central dopamine metabolism and thus may be of value in assessing the role of dopamine neurotransmission in schizophrenia. Furthermore, some recent studies have suggested a relationship of pHVA with symptomatology. We have undertaken a study of pHVA in a large cohort of unmedicated DSM-IV schizophrenic patients in order to assess the relationship of pHVA to various clinical parameters. pHVA in 58 drug-free patients (10.11+/-0.52 ng/ml) was significantly elevated in comparison with 62 matched control subjects (8.77+/-0.39 ng/ml). pHVA was found to be higher in patients with a more negative syndrome. No significant correlation of pHVA with overall SAPS or SANS scores was apparent in the patients although, within the SANS subscales, a significant relationship to anhedonia-asociality was apparent. Interestingly, the male drug-free patients showed a correlation of pHVA with negative symptoms defined by SANS and several SANS subscales, while females showed no significant relationship with any SANS subscales. The results may suggest that an increased dopaminergic turnover is apparent in (male) schizophrenic patients with predominantly negative symptoms, providing some support for reports that this change in neuronal activity may be related to the neuropathological abnormalities seen in the disease, which may themselves differ between males and females. Such neuronal deficits of developmental or degenerative origin may thus result in an elevation/disinhibition of central dopamine metabolism in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11287053     DOI: 10.1016/s0022-3956(01)00008-5

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  7 in total

1.  Variability of plasma homovanillic acid over 13 months in patients with schizophrenia; relationship with the clinical response and the Wisconsin card sort test.

Authors:  Mercedes Zumárraga; Miguel A González-Torres; Aurora Arrue; Ricardo Dávila; Wendy Dávila; Lucía Inchausti; Lucía Pérez-Cabeza; Aránzazu Fernández-Rivas; Sonia Bustamante; Nieves Basterreche; José Guimón
Journal:  Neurochem Res       Date:  2011-04-08       Impact factor: 3.996

2.  Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure.

Authors:  David E Gard; Ann M Kring; Marja Germans Gard; William P Horan; Michael F Green
Journal:  Schizophr Res       Date:  2007-05-09       Impact factor: 4.939

3.  Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia.

Authors:  Tomiki Sumiyoshi; A Roy; C-H Kim; K Jayathilake; M A Lee; C Sumiyoshi; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

4.  Plasma homovanillic acid and prolactin in Huntington's disease.

Authors:  Manolis Markianos; Marios Panas; Nikos Kalfakis; Dimitrios Vassilopoulos
Journal:  Neurochem Res       Date:  2008-10-08       Impact factor: 3.996

5.  The validity of Psychosis Proneness Scales as vulnerability indicators in recent-onset schizophrenia patients.

Authors:  William P Horan; Steven P Reise; Kenneth L Subotnik; Joseph Ventura; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2008-01-24       Impact factor: 4.939

6.  Neuropsychological measures of attention and memory function in schizophrenia: relationships with symptom dimensions and serum monoamine activity.

Authors:  Robert D Oades; Bernd Röpcke; Uwe Henning; Ansgard Klimke
Journal:  Behav Brain Funct       Date:  2005-08-09       Impact factor: 3.759

7.  Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion.

Authors:  Tanja Veselinović; Ingo Vernaleken; Paul Cumming; Uwe Henning; Lina Winkler; Peter Kaleta; Michael Paulzen; Christian Luckhaus; Gerhard Gründer
Journal:  Neuropsychiatr Dis Treat       Date:  2018-04-27       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.